Fo¨rster (fluorescence) resonance energy transfer (FRET) and fluorescence polarization (FP) are widely used technologies for monitoring bimolecular interactions and have been extensively used in highthroughput screening (HTS) for probe and drug discovery. Despite their popularity in HTS, it has been recognized that different assay technologies may generate different hit lists for the same biochemical interaction. Due to the high cost of large-scale HTS campaigns, one has to make a critical choice to employee one assay platform for a particular HTS. Here we report the design and development of a dualreadout HTS assay that combines two assay technologies into one system using the Mcl-1 and Noxa BH3 peptide interaction as a model system. In this system, both FP and FRET signals were simultaneously monitored from one reaction, which is termed ''Dual-Readout F 2 assay'' with F 2 for FP and FRET. This dual-readout technology has been optimized in a 1,536-well ultra-HTS format for the discovery of Mcl-1 protein inhibitors and achieved a robust performance. This F 2 assay was further validated by screening a library of 102,255 compounds. As two assay platforms are utilized for the same target simultaneously, hit information is enriched without increasing the screening cost. This strategy can be generally extended to other FP-based assays and is expected to enrich primary HTS information and enhance the hit quality of HTS campaigns.
INTRODUCTION
P rotein-protein interactions are involved in the control of diverse physiological and pathological processes in living organisms such as cell apoptosis and proliferation, which represent an emerging class of molecular targets for novel drug discovery. 1 To monitor molecular interactions, a number of assay technologies have been developed, such as timeresolved Fö rster (or fluorescence) resonance energy transfer (TR-FRET), fluorescence polarization (FP), and surface plasmon resonance. [2] [3] [4] [5] These assay technologies, particularly in homogenous format, have been extensively used in high-throughput screening (HTS) campaigns for the identification of new chemical entities in the drug discovery field and new molecular probes for chemical biology studies. 5 However, the application of different assay technologies often gives rise to different hit lists even when monitoring the same biochemical interaction. Because of the high cost of screening large chemical libraries, HTS campaigns are often conducted in a single-point format and investigators are forced to choose a single-assay technology. To enhance the efficiency of HTS campaigns, we have designed and developed a novel HTS technology that allows the generation of two HTS readouts from one reaction by combining FRET and FP technologies into one platform. This technology is termed dual-readout F 2 assay, where F 2 standing for FRET and FP. We have further miniaturized the F 2 assay to a 1,536-well ultra-HTS (uHTS)
ABBREVIATIONS: DMSO, dimethyl sulfoxide; FI, fluorescence intensity; FOC, fold of control; FP, fluorescence polarization; HTS, high-throughput screening; mP, millipolarization; S/B, signal-to-background ratio; SD, standard deviation; S/N, signal-to-noise ratio; TMR, 5/6-carboxytetramethyl-rhodamine; TR-FRET, time-resolved fluorescence resonance energy transfer; uHTS, ultra high-throughput screening.
format. To provide a proof of concept, this F 2 uHTS assay technology was used to monitor the interaction of Mcl-1 and Noxa for the eventual goal of discovering the next generation of small molecule modulators of apoptosis. Apoptosis, or programmed cell death, is a critical process in both development and homeostasis of multicellular organisms. 6 Alterations in apoptotic pathways can disrupt the delicate balance between cell proliferation and cell death and lead to a variety of diseases. 6, 7 Mcl-1 belongs to the prosurvival Bcl-2 subfamily along with Bcl-X L , Bcl-2, Bcl-w, and A1. [7] [8] [9] Mcl-1 is overexpressed in many human cancers and its overexpression contributes to chemoresistance and disease relapse. [10] [11] [12] Recently, a number of groups have reported the discovery of small-molecules known as BH3 mimetics, which induce apoptosis by inhibiting antiapoptotic Bcl-2 family members. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] This family of molecules demonstrates a wide range of both potency and selectivity for different antiapoptotic Bcl-2 proteins. However, there is still a need for developing BH3 mimetics that can efficiently and selectively target Mcl-1 protein.
One of the essential elements in discovering and identifying smallmolecule Mcl-1 inhibitors is the development of a robust, quantitative, and high-throughput assay for evaluation of the binding affinities of potential small molecule inhibitors. In vitro binding studies have demonstrated that BH3 peptides from pro-apoptotic proteins exhibit preferences in binding to anti-apoptotic proteins (Bcl-2, Bcl-xL, and Mcl-1). 24 Noxa BH3 peptide is highly selective for Mcl-1 and Bcl-2A1
proteins (within the nM range) but does not bind detectably to the other members of this family (>100 mM). 24 Recently published structures of 
MATERIALS AND METHODS

Peptides
All the peptides were synthesized at Emory Microchemistry and Proteomic Facility. The 26-mer Noxa peptide (residues 18-43: PAELEVECATQLRRFGDKLNFRQKLL-NH 2 ) used in this study was synthesized and labeled with 5/6-carboxytetramethyl-rhodamine (TMR). The nonlabeled Noxa peptide and 21-residue Bid-BH3 peptide (residues 79-99; QEDIIRNIARHLAQVGDSMDR-NH 2 ) were synthesized and used as peptide antagonists.
Expression and Purification of Recombinant Mcl-1 Protein
Human Mcl-1 cDNA was purchased from Origene. The Mcl-1 fragment, amino acid residues 171-327, was cloned into the pHis-TEV vector (a modified pET vector) through BamHI and EcoRI sites, using the oligonucleotides: 5'-CGGGATCCGAGGACGAGTT GTACCG-GCAG-3' and 5'-GGAATTCCTAGCCAC-CTTCTAGGTCCTC TAC-3'. Mcl-1 protein with an N-terminal 6xHis tag was produced in Escherichia coli BL21 (DE3) cells. Cells were grown at 378C in 2xYT containing antibiotics to an OD 600 of 0.6. Protein expression was induced by 0.4 mM isopropyl b-D-1-thiogalactopyranoside at 378C for 4 h. Cells were lysed in 50 mM Tris pH 8.0 buffer containing 500 mM NaCl, 0.1% bME, and 40 mL of Leupeptin/Aprotin. Mcl-1 protein was purified from the soluble fraction using Ni-NTA resin (Qiagen), following the manufacturer's instructions. The protein was further purified on a Source Q15 column (resin and column are from Amersham Biosciences) in 25 mM Tris pH 8.0 buffer, with NaCl gradient. The purified recombinant Mcl-1 protein was stored at À808C in following buffer: 25 mM Tris pH 8.0, 100 mM NaCl, 5 mM DTT, and 25% glycerol.
Dual FRET/FP Measurements
TR-FRET and FP measurements were performed using black 1,536-well plates (Corning Costar, Cat# 3724) in an Envision Multilabel plate reader (Perkin Elmer Life Sciences). To each well, a mixture of TMR-Noxa peptide, Mcl-1 protein, and terbium-anti-His antibody (His-Tb) were added to a final volume of 5 mL in the assay buffer (20 mM Tris buffer, pH 7.5, 50 mM NaCl, and 0.01% NP40). The TR-FRET and FP signals were measured from the same well either in TR-FRET or FP module with an Envision Multilabel plate reader.
In the TR-FRET readout, Mcl-1 protein with a 6xHis tag was indirectly labeled with the terbium through a terbium-conjugated anti-6xHis antibody (LanthaScreenÔ; Invitrogen). Terbium and rhodamine comprise a fluorescence energy transfer pair. Interaction of Mcl-1 protein with TMR-Noxa peptide brings two conjugated fluorophores into proximity, leading to an energy transfer from terbium to rhodamine and the generation of FRET signals (Fig. 1) . FRET signal is detected in an Envision Multilabel plate reader with a laser excitation at 337 nm, and emission at 545-7 and 572-7.5 nm to measure the fluorescence signal from terbium and rhodamine, with a dual-dichroic mirror at 400/555 nm. The delay time is set at 100 ms. In the FP readout, the same reaction mixtures for TR-FRET readout were used to measure the FP signals using the FP module (Fig. 1) 
High-Throughput Assay Performance
To evaluate the quality and suitability of the dual-readout F , and terbium-anti-His (2 nM) was dispensed into 1,536-well assay plates using a MultiDrop Combi (Thermo-Fisher Scientific). Then, compounds (0.1 mL; 1 mM in 100% DMSO) in 384-well storage plates (Corning) were transferred to 1,536-well assay plates using a PinTool (VP Scientific) integrated with Beckman NX liquid handler (Beckman Coulter). The reactions were mixed thoroughly using the shaker integrated with BeckmanNX and incubated at room temperature for 1 h. The plates were delivered through integrated robotic systems to the Envision multimode reader as described above for recording TR-FRET and FP signals. Screening data were analyzed using the CambridgeSoft Software (CambridgeSoft Corporation).
RESULTS AND DISCUSSIONS
Design of the Dual-Readout F 2 Assay
FRET and FP are two most widely used fluorescence-based homogenous HTS technologies for monitoring bimolecular interactions. FRET is a nonradioactive, photophysical effect in which energy that is absorbed by a donor fluorophore is transferred to an acceptor fluorophore. 29 Energy transfer from donor to acceptor fluorophores occurs when (1) the emission spectrum of the donor fluorophore significantly overlaps with the absorption spectrum of the acceptor fluorophore; (2) the donor and acceptor transition dipole orientations are approximately parallel; and (3) the donor and acceptor molecules are in close proximity (10-100 Å ). By coupling the donor and acceptor fluorophores to two interacting molecules, the fluorophores may be brought into close proximity and induce a FRET signal. The attractive feature of TR-FRET is the time delay of the signal measurement, which reduces the prompt autofluorescence from tested library compounds. FP is a sensitive nonradioactive technique for the study of biomolecular interactions in solution. When fluorescent small molecules (such as tagged peptides) in solution are bound by large molecules (such as a protein), the movement of the resulting complex becomes slower. In this way, the binding of a fluorescently labeled peptide to a protein can be monitored by the change in emitted polarization signals. TR-FRET or FP assay format is usually employed individually for a specific HTS campaign. However, it is well documented that different assay and detection technologies, such as FRET versus FP, can generate quite different hit lists for the same biochemical interaction. [30] [31] [32] To enhance the quality of the hit list from primary screens, this study evaluated the feasibility of combining two assay formats, FRET and FP, into one HTS reaction, in which both FRET and FP signals were read from the same well. The Mcl-1 and Noxa interaction involved in apoptosis regulation was used as a model system. For the F 2 assay design, epitope-tagged Mcl-1 protein is indirectly labeled with a TR-FRET donor, terbium, through terbium-conjugated anti-epitopeantibody (Fig. 1) . Noxa peptide is directly labeled with a corresponding acceptor fluorophore, TMR, for terbium pairing in this case. For the TR-FRET readout, the binding of TMR-labeled Noxa peptide to Mcl-1 bring donor (terbium) and acceptor (TMR) into proximity, leading to the energy transfer from terbium to TMR upon excitation and the generation of the FRET signal, which can be detected at 572 nm. 
Dual-Readout F 2 Assay Development
Analysis and optimization of TMR-labeled Noxa peptide in the dualassay platform. The key point for the successful dual TR-FRET/FP assay is to choose the assay conditions optimal for both assays in the same reaction. We first evaluated the concentrations of TMRNoxa-peptide optimal for the dual measurements. Increasing concentrations of TMR-Noxa-peptide were mixed with constant amount of terbium-anti-His antibody in the presence or absence of Mcl-1 protein (50 nM). Five microliters of the mixture was transferred to a 1,536-well plate, and TR-FRET signal, FP signal, and fluorescence intensity (FI) for TMR-labeled Noxa peptide were measured using the Envision plate reader. For FP measurement, the tracer's fluorescent quantum yield has to be significantly higher than that of the background (buffer) itself. 33 As shown in Figure 2A , as low as 4 nM of TMR-Noxa-peptide alone, the FI signal from tracer is >15 times higher than background from buffer-only wells and reached about 1,100 times higher at 250 nM of the tracer. At around 500 nM of TMR-Noxa peptide, the detected FI signal was saturated and reached the maximum detection limitation using the current reader settings, which already generated a wide range of signal window between 1 and 1,100 times. The goal of the designed dual-readout F 2 assay is to provide a multiplexed assay platform that is simple for routine use as well as applicable for HTS or uHTS. Therefore, we evaluated the dual-readout assay performance through assessing its Z' factor in both TR-FRET and FP measurement, S/B of the TR-FRET read, and S/N of the FP (Fig. 2D) . The S/B of TR-FRET signal at 125 nM of TMRNoxa peptide was about 8.6 and achieved maximum (9.1) when 250 nM of TMR-Noxa peptide was tested. The S/N of the FP read was 20 at 62.5 nM of TMR-Noxa peptide and reached saturation at 62.5 nM or higher concentrations of TMR-Noxa peptide. Z' factors were all above 0.5 for both TR-FRET and FP readouts when higher than 30 nM of TMR-Noxa peptide were tested (Fig. 2E) , indicating a robust and high-quality assay for HTS. 34 The Kds obtained by TR-FRET and FP measurements for the same reaction appear to be distinct. The Kd for the binding of TMR-Noxa peptide to 50 nM of Mcl-1 measured in the TR-FRET read (85.5 nM) is *32.9 times higher that the Kd obtained from FP read (2.6 nM). This may be due to the different signal strength measured by a given fluorophore-ligand concentration in each assay format. The FP assay format is amenable to using a lower fluorophore-ligand concentration than the TR-FRET assay format. To achieve high enough signal and remain within the dynamic range of the assay for both TR-FRET and FP measurements, the concentrations of TMR-Noxa peptide used in the dual-readout assays need to be carefully selected. For the FP assay format, when used at a lower concentration of the fluorophore, fluorescence contributions from library compound will have a more dramatic impact on the assay because the detection readout is a measure of the sum of all fluorescent species in the assay. As the fluorophore concentration increases in the assay, the contributions from fluorescent compounds are reduced. Therefore, the use of higher concentrations of fluorophore-labeled ligand would have the advantage to reduce the fluorescence interference from library compounds in the FP assay format. 35 Thus, based on the titration curves (Fig. 3A) . The TR-FRET signal reached a maximum when 31.3 nM of Mcl-1 protein was mixed with 62.5 nM of TMR-Noxa, or when 62.5 nM of Mcl-1 was incubated with 125 nM of TMR-Noxa peptide, respectively. The estimated Kd of Mcl-1 was 6.2 and 20.6 nM, respectively, under these two conditions.
read. Binding of 50 nM Mcl-1 to increasing concentrations of TMRNoxa peptide resulted in an increase in both S/B (TR-FRET) and S/N (FP) values
In the FP measurement, as the amount of Mcl-1 protein increased, progressively increased FP signal was observed until reaching saturation. A maximum assay window about 100 mP was achieved. The Kds for the binding to 62.5 and 125 nM of TMR-Noxa peptide in the FP read were 11.5 and 20.5 nM, respectively. Both TR-FRET and FP assays from the same reaction gave rise to a consistent and robust assay performance. The Kd of the Mcl-1 binding to 125 nM of TMR-Noxa peptide was 20.6 nM in the TR-FRET read and 20.5 nM in the FP read (Fig. 3C) . Mcl-1 protein at 62.5 nM generated the maximum S/B (10.6) in the TR-FRET read and S/N (25.1) in the FP read (Fig. 3D) . Further increasing Mcl-1 protein concentration led to decreased signals in TR-FRET readout, although the FP readout remained constant (Fig. 3C, D) . Z' factors were above 0.5 for both TR-FRET and FP readouts when Mcl-1 protein concentrations were >7.8 nM. From these analyses, it appears that it is feasible to identify assay conditions that permit the optimal performance by both TR-FRET and FP assay types for the Mcl-1/Noxa interaction. Accordingly, an assay condition that utilizes 125 nM of TMR-Noxa peptide and 62.5 nM of Mcl-1 protein was selected and used for the following studies. With this assay condition, optimized performance regarding assay window and robustness can be achieved for both TR-FRET and FP measurement.
Validation of the Dual-Readout F 2 Technology in a Competition Assay
To validate the dual-readout F 2 assay format for HTS, we have developed a competition assay by using unlabeled Noxa peptide. The unlabeled Noxa peptide is expected to compete with the TMR-Noxa for Mcl-1 binding. Indeed, the addition of unlabeled Noxa-peptide dose-dependently decreased both TR-FRET and FP signals (Fig. 4) . 
uHTS Format Development
To evaluate the suitability of the dual-readout F 2 technology for the identification of Mcl-1 inhibitors in an uHTS format, DMSO tolerance and stability of the assay were examined. DMSO is a common solvent used in dissolving many natural and organic compounds as employed in generating small molecular libraries for HTS. To access the full applicability of dual-readout F 2 for uHTS, it is necessary to test the effect of the DMSO on the assay performance before screening for Mcl-1 protein inhibitors. For this purpose, both TR-FRET and FP signals were recorded upon the addition of increasing concentrations of DMSO to wells in a 1,536-well plate. As shown in Figure 5 , the FRET as well as FP readouts remained unchanged in the presence of up to 2.3% (v/v) DMSO. Further increase of DMSO slightly decreased the FP signal and significantly interfered with the TR-FRET signal. These results indicate that dual-readout F 2 -based Mcl-1 uHTS assay can be reliably performed in the presence of up to 2.3% DMSO. Good temporal stability upon compound addition would be a highly attractive feature for the uHTS assay and particularly for the uHTS campaign. Thus, we examined the stability of the dual-readout (Fig. 5C ) and the FP read (Fig. 5D) at both time points. Such assay stability in the presence of an antagonist allows for the large batch sizes typical of uHTS screens.
Validation of the Dual-Readout F 2 -Based Mcl-1 Assay in an uHTS Format
To be amenable for uHTS, the dual-readout F 2 assay should exhibit minimal variation between well-to-well, plate-to-plate, and day-today operations. To test the utility of our optimized dual-readout assay in an uHTS format, we examined the precision and robustness of the assay in eighty 1,536-well microplates performed in a low volume on different days. About 4. (Fig. 6A) and FP reads ( Fig. 6B) with large assay windows. The average TR-FRET signal from 80 plates was 1,553.6 cps with an SD of 136.8. The average FP signal was 133.9 mP with an SD of 10.2. To further evaluate the applicability of the dual-readout F 2 technology for the 1,536-well based uHTS, the assay performance parameter S/B (TR-FRET), S/N (FP), and Z' factors were calculated. The S/B values for TR-FRET readout, as determined for each plate, were consistently higher than 5 and the average value was 6.2 from 80 plates with an SD of 0.8 (Fig. 6C) . The S/N values for the FP read were constantly higher than 8 and the average was 8.8
with an SD of 0.5 (Fig. 6C) . The Z' factors were all above 0.5 for both TR-FRET read and FP read (Fig. 6D) , demonstrating a robust and consistent assay with minimal variations. Thus, the dual-readout F 2 -based Mcl-1/Noxa binding assay in 1,536-well plate is of excellent quality for uHTS.
To test the utility of the dual-readout F 2 assay for uHTS, we performed a screening using a 102,255-compound library from the Molecular Library Screening Center Network. Library compounds (0.1 mL of 1 mM stock in DMSO) were dispensed into 1,536-well plates . The final compound concentration was 21.7 mM with a final DMSO concentration of 2.2%. Analysis of the TR-FRET-derived data revealed a total of 1,568 positive compounds that decreased the TR-FRET assay window by >50% with a hit rate of 1.5% (Fig. 7A) . Compounds with intrinsic fluorescence or fluorescence-quenching properties were identified by the FI at 545 nm. Fold of control (FOC) was calculated by FI of 545 nm from compound wells over that from vehicle control wells. FI artifacts were defined by FOC 0.2 (80% quenching) or ! 2 (twofold fluorescence over the control). Among those 1,568 positives obtained from TR-FRET, 53 compounds were possible artifact compounds, which resulted in an artifact rate of 3.4%.
On the other hand, the FP readout gave rise to 325 positives when the hit cutoff was set at 50% inhibition of FP assay window compared to DMSO control wells (Fig. 7B) . p-Channel FI of the FP read was used for reference to identify fluorescent or fluorescence-quenching compounds in FP readout. FI of the compound was expressed as FOC and calculated as p-channel counts from compound well over that from vehicle control wells. Fifty-seven compounds have been found to interfere with the assay with fluorescence (FI ! 2) or fluorescence quenching (FI 0.2). The artifact rate was 21.3%.
These data indicate that FP readout generates higher artifact rate (21.3%) than that from TR-FRET readout (3.4%), suggesting that FP assay might be more sensitive to fluorescence interference from screening compounds, which is consistent with previous reports. 35 When we plotted the FI of FP from the compound against FI of TR-FRET, we found that some compounds interfered only with the FP readout or TR-FRET, whereas some fluorescent-quenching compounds interfered with both readouts.
Interestingly, most of FP-derived positives also showed up as positives in the TR-FRET assay format (Fig. 7C) . Two hundred fiftynine compounds showed % inhibition > 50 in both TR-FRET and FP readout with 52 fluorescence-interfering compounds, resulting in 207 top hits. Thus, by requiring that a hit be positive in both TR-FRET and FP readouts, the strategy using the dual readouts would expect to greatly reduce the number of false positives that are caused by compound fluorescence or quenching at the wavelengths employed in either assay. Therefore, the dual F 2 assay technology allows us to better rank and prioritizes hits from HTS and enables the selection of high quality hits for the follow-up studies. Interestingly, 1,268 compounds were identified as positives only in the TR-FRET assay and 60 positive compounds were exclusive to the FP readout (Fig. 7C) . This suggests that different assay technologies may generate different hit list, which is consistent with previous reports. 31 With the advances of the instrumentation and the precision of the modern liquid-handling technologies, the variation issue of HTS has been drastically reduced. Simply repeating the screening will not significantly change the hit list. While falsepositive issues have been extensively addressed in the HTS field, false-negatives have not gained much attention primarily because that large-scale screening for one target using multiple platforms is not practical. To avoid potential pitfalls, titration of both assay components in the presence of a broad range of multiple concentrations of its counterpart, often around a reported Kd value, would be critical to achieve an optimized condition. Compilation of these data would help selecting the most appropriate ratio and concentrations of the two assay components, specifically advantageous for protein-peptide pairs with a priori unknown affinities. Further validation of the dual-readout F 2 assay by screening a 102,255-compound library revealed that the number of positives in dual readouts was less than that from a single-readout platform. These dual-positive hits after the exclusion of false-positives, such as fluorescent compounds or quenchers, as shown in Figure 7 , should be selected as primary positives for secondary and biological validation assays. As two assay formats are utilized for the same target at the same time in the same reaction, the dual-readout F 2 technology is likely to minimize the number of false-positives and false-negatives, enrich primary HTS information, and increase screening quality and efficiency.
